文献速递妇科

NSGO-FANDANGO/ENGOT-EN1:尼达尼布或安慰剂联合一线化疗治疗晚期或复发性子宫内膜癌的随机II期研究

NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2025-06-30

该随机II期研究纳入146例晚期或复发性子宫内膜癌患者,1:1随机接受尼达尼布或安慰剂联合卡铂/紫杉醇化疗及维持治疗。中位随访43.9个月,尼达尼布组与安慰剂组中位无进展生存期分别为8.2个月和7.1个月(HR 0.99,95%CI 0.69-1.43,p=0.992),总生存期无差异(HR 0.82,96%CI 0.54-1.25,p=0.365)。尼达尼布组3-4级不良事件更高。

要点

  • 尼达尼布联合化疗未改善晚期或复发性子宫内膜癌的无进展生存期和总生存期。
  • 尼达尼布组3-4级丙氨酸氨基转移酶升高(18.1% vs 4.1%)和腹泻(10.8% vs 1.3%)发生率高于安慰剂组。
  • 作者不推荐对该方案进行III期评估。

核心结论

  • 在化疗基础上加用尼达尼布未改善无进展生存期,也未改善总生存期。
  • 作者不推荐对该方案进行III期评估。

研究设计与样本

  • 随机、双盲、安慰剂对照II期研究,纳入组织学确诊的FIGO 2009 IIIC2-IV期或复发性子宫内膜癌患者。
  • 2016年11月30日至2019年1月11日共146例参与者(平均年龄66.1岁)随机并至少接受一剂尼达尼布或安慰剂:尼达尼布+TC组72例,安慰剂+TC组74例。
  • 尼达尼布200 mg或安慰剂每日两次,化疗期间第2-21天给药,化疗为每21天一次卡铂(AUC5)联合紫杉醇(175 mg/m2)共六周期,之后维持治疗直至疾病进展、不可接受毒性或撤回知情同意。
  • 主要终点为无进展生存期。

主要发现

  • 中位随访43.9个月(95%CI 41.8-45.6),尼达尼布+TC组中位无进展生存期为8.2个月(95%CI 5.77-10.27),安慰剂+TC组为7.1个月(95%CI 5.40-9.10)(HR 0.99,95%CI 0.69-1.43,p=0.992)。
  • 中位总生存期无差异(HR 0.82,96%CI 0.54-1.25,p=0.365)。
  • 治疗中出现3-4级不良事件在尼达尼布+TC组高于安慰剂+TC组,尤其是血丙氨酸氨基转移酶升高(18.1% vs 4.1%)和腹泻(10.8% vs 1.3%)。

临床怎么用

  • 作者不推荐对该方案进行III期评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with advanced or recurrent endometrial cancer (EC) have poor prognosis despite treatment with combination chemotherapy. This study explored the preliminary efficacy of the potent oral tyrosine kinase inhibitor nintedanib (N), in addition to chemotherapy. METHODS: Patients with histologically confirmed stage FIGO 2009 stage IIIC2-IV or recurrent EC were randomized 1:1 to receive N 200 mg or placebo (P), twice daily days 2-21 during chemotherapy (six cycles of Carboplatin (AUC5) and paclitaxel (175 mg/m2) every 21 days (TC)) and in maintenance until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was progression-free survival (PFS). RESULTS: Between November 30th, 2016, and January 11th, 2019 146 participants (mean age 66.1 years) were randomized and had received at least one dose of N/P: 72 patients to the N + TC arm and 74 to the P + TC arm. After median follow-up time of 43.9 months (95 % CI: 41.8-45.6), median PFS was 8.2 63 months (95 % CI: 5.77-10.27) in the N + TC arm and 7.1 months (95 % CI: 5.40-9.10) in the P + TC arm (HR 0.99, 95 % CI: 0.69-1.43, p = 0.992). There was no difference in median overall survival (OS) (HR 0.82; 96 % CI: 0.54-1.25, p = 0.365). Treatment-emergent grade 3-4 adverse events were higher in N + TC vs P + TC arm, in particular increase in blood alanine aminotransferase (18.1 % vs 4.1 %) and diarrhea (10.8 % and 1.3 %). CONCLUSIONS: Addition of nintedanib to chemotherapy did not improve PFS nor OS. Phase III evaluation of this regimen is not recommended.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lindemann K, Berton D, Sehouli J, et al. NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. Gynecol Oncol. 2025. PMID: 40592025. doi:10.1016/j.ygyno.2025.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。